Rheb signaling and tumorigenesis: MTORC1 and new horizons

International Journal of Cancer

Volumn 138, Issue 8, 2016, Pages 1815-1823

  Armijo, Marisol E ^a   Campos, Tania ^a   Fuentes Villalobos, Francisco ^a   Palma, Mario E ^a   Pincheira, Roxana ^a   Castro, Ariel F ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

mTORC1; mTORC1 independent Rheb functions; rapamycin resistance; Rheb

Indexed keywords

CASPASE ACTIVATED DEOXYRIBONUCLEASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RHEB PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MULTIPROTEIN COMPLEX; NEUROPEPTIDE; RHEB PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CANCER CELL; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR RESISTANCE; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; HUMANS; MONOMERIC GTP-BINDING PROTEINS; MULTIPROTEIN COMPLEXES; NEUROPEPTIDES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84958873711     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29707     Document Type: Review

References (101)

1. Gromov PS, Madsen P, Tomerup N, et al., A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog of rheb. FEBS Lett 1995; 377: 221-6.
2. Urano J, Tabancay AP, Yang W, et al., The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake. J Biol Chem 2000; 275: 11198-206.
3. Yamagata K, Sanders LK, Kaufmann WE, et al., rheb, a growth factor-and synaptic activity-regulated gene, encodes a novel Ras-related protein. J Biol Chem 1994; 269: 16333-9.
4. Aspuria P-J, Tamanoi F., The Rheb family of GTP-binding proteins. Cell Signal 2004; 16: 1105-12.
5. Clark GJ, Kinch MS, Rogers-Graham K, et al., The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 1997; 272: 10608-15.
6. Long X, Lin Y, Ortiz-Vega S, et al., Rheb binds and regulates the mTOR kinase. Curr Biol 2005; 15: 702-13.
7. Mach KE, Furge KA, Albright CF., Loss of Rhb1, a Rheb-related GTPase in fission yeast, causes growth arrest with a terminal phenotype similar to that caused by nitrogen starvation. Genetics 2000; 155: 611-22.
8. Panepinto JC, Oliver BG, Amlung TW, et al., Expression of the Aspergillus fumigatus rheb homologue, rhbA, is induced by nitrogen starvation. Fungal Genet Biol 2002; 36: 207-14.
9. Saucedo LJ, Gao X, Chiarelli DA, et al., Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol 2003; 5: 566-71.
10. Takai Y, Sasaki T, Matozaki T., Small GTP-binding proteins. Physiol Rev 2001; 68: 153-208.
11. Patel PH, Thapar N, Guo L, et al., Drosophila Rheb GTPase is required for cell cycle progression and cell growth. J Cell Sci 2003; 116: 3601-10.
12. Stocker H, Radimerski T, Schindelholz B, et al., Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 2003; 5: 559-65.
13. Castro AF, Rebhun JF, Clark GJ, et al., Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003; 278: 32493-6.
14. Garami A, Zwartkruis FJT, Nobukuni T, et al., Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11: 1457-66.
15. Inoki K, Li Y, Xu T, et al., Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17: 1829-34.
16. Tee AR, Manning BD, Roux PP, et al., Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13: 1259-68.
17. Zhang Y, Gao X, Saucedo LJ, et al., Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5: 578-81.
18. Inoki K, Ouyang H, Li Y, et al., Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 2005; 69: 79-100.
19. Kim D-H, Sarbassov DD, Ali SM, et al., mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-75.
20. Loewith R, Jacinto E, Wullschleger S, et al., Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10: 457-68.
21. Sarbassov DD, Ali SM, Kim D-H, et al., Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302.
22. Yang Q, Inoki K, Kim E, et al., TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci USA 2006; 103: 6811-1 6.
23. Zhou H, Huang S., The complexes of mammalian target of rapamycin. Curr Protein Pept Sci 2010; 11: 409-24.
24. Ma XM, Blenis J., Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-18.
25. Thoreen CC, Kang SA, Chang JW, et al., An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023-32.
26. Menon S, Dibble CC, Talbott G, et al., Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 2014; 156: 771-85.
27. Sancak Y, Bar-Peled L, Zoncu R, et al., Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010; 141: 290-303.
28. Zhang J, Kim J, Alexander A, et al., A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. Nat Cell Biol 2013; 15: 1186-96.
29. Li Y, Wang Y, Kim E, et al., Bnip3 mediates the hypoxia-induced inhibition on mammalian Target of Rapamycin by interacting with Rheb. J Biol Chem 2007; 282: 35803-13.
30. Lee MN, Ha SH, Kim J, et al., Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Mol Cell Biol 2009; 29: 3991-4001.
31. Bai X, Ma D, Liu A, et al., Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007; 318: 977-80.
32. Ma D, Bai X, Guo S, et al., The switch I region of Rheb is critical for its interaction with FKBP38. J Biol Chem 2008; 283: 25963-70.
33. Uhlenbrock K, Weiwad M, Wetzker R, et al., Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway. FEBS Lett 2009; 583: 965-70.
34. Wang X, Fonseca BD, Tang H, et al., Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 2008; 283: 30482-92.
35. Sun Y, Fang Y, Yoon M-S, et al., Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci USA 2008; 105: 8286-91.
36. Fang Y, Park I-H, Wu A-L, et al., PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr Biol 2003; 13: 2037-44.
37. Hsu Y-C, Chern JJ, Cai Y, et al., Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 2007; 445: 785-8.
38. Rehmann H, Brüning M, Berghaus C, et al., Biochemical characterisation of TCTP questions its function as a guanine nucleotide exchange factor for Rheb. FEBS Lett 2008; 582: 3005-10.
39. Nellist M, van Slegtenhorst MA, Goedbloed M, et al., Characterization of the cytosolic tuberin-hamartin complex. J Biol Chem 1999; 274: 35647-52.
40. Plank TL, Yeung RS, Henske EP., Hamartin, the product of the Tuberous Sclerosis 1 (TSC1) gene, interacts with Tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998; 58: 4766-70.
41. Van Slegtenhorst M, Nellist M, Nagelkerken B, et al., Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998; 7: 1053-7.
42. Potter CJ, Huang H, Xu T., Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001; 105: 357-68.
43. Tapon N, Ito N, Dickson BJ, et al., The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 2001; 105: 345-55.
44. Dibble CC, Elis W, Menon S, et al., TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell 2012; 47: 535-46.
45. Buerger C, DeVries B, Stambolic V., Localization of Rheb to the endomembrane is critical for its signaling function. Biochem Biophys Res Commun 2006; 344: 869-80.
46. Hanker AB, Mitin N, Wilder RS, et al., Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene 2010; 29: 380-91.
47. Takahashi K, Nakagawa M, Young SG, et al., Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem 2005; 280: 32768-74.
48. Yang W, Tabancay AP, Urano J, et al., Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Mol Microbiol 2001; 41: 1339-47.
49. Basso AD, Mirza A, Liu G, et al., The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 2005; 280: 31101-8.
50. Fawal M-A, Brandt M, Djouder N., MCRS1 binds and couples Rheb to amino acid-dependent mTORC1 activation. Dev Cell 2015; 33: 67-81.
51. Apolloni A, Prior IA, Lindsay M, et al., Hras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol Cell Biol 2000; 20: 2475-87.
52. Rosner M, Hanneder M, Siegel N, et al., The mTOR pathway and its role in human genetic diseases. Mutat Res 2008; 659: 284-92.
53. Crino PB, Nathanson KL, Henske EP., The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345-6.
54. Li J, Kim SG, Blenis J., Rapamycin: one drug, many effects. Cell Metab 2014; 19: 373-9.
55. Bissler JJ, McCormack FX, Young LR, et al., Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-51.
56. Bissler JJ, Kingswood JC, Radzikowska E, et al., Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-24.
57. McCormack FX, Inoue Y, Moss J, et al., Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-606.
58. Benjamin D, Colombi M, Moroni C, et al., Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868-80.
59. Kang YJ, Lu M-K, Guan K-L., The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ 2011; 18: 133-44.
60. Karassek S, Berghaus C, Schwarten M, et al., Ras homolog enriched in brain (Rheb) enhances apoptotic signaling. J Biol Chem 2010; 285: 33979-91.
61. Zhou X, Ikenoue T, Chen X, et al., Rheb controls misfolded protein metabolism by inhibiting aggresome formation and autophagy. Proc Natl Acad Sci USA 2009; 106: 8923-8.
62. Johnston JA, Ward CL, Kopito RR., Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143: 1883-98.
63. Lacher MD, Pincheira R, Zhu Z, et al., Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene 2010; 29: 6543-56.
64. Lu ZH, Shvartsman MB, Lee AY, et al., Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res 2010; 70: 3287-98.
65. Lassman AB, Rossi MR, Raizer JJ, et al., Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005; 11: 7841-50.
66. Nardella C, Chen Z, Salmena L, et al., Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 2008; 22: 2172-7.
67. Mavrakis KJ, Zhu H, Silva RLA, et al., Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 2008; 22: 2178-88.
68. Lawrence MS, Stojanov P, Mermel CH, et al., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
69. Grabiner BC, Nardi V, Birsoy K, et al., A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 2014; 4: 554-63.
70. Zheng H, Liu A, Liu B, et al., Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Lett 2010; 297: 117-25.
71. Ding H, McDonald JS, Yun S, et al., Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica 2014; 99: 60-9.
72. Im E, von Lintig FC, Chen J, et al., Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 2002; 21: 6356-65.
73. Yee WM, Worley PF., Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals. Mol Cell Biol 1997; 17: 921-33.
74. Karbowniczek M, Cash T, Cheung M, et al., Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 2004; 279: 29930-7.
75. Karbowniczek M, Robertson GP, Henske EP., Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem 2006; 281: 25447-56.
76. Melser S, Chatelain EH, Lavie J, et al., Rheb regulates mitophagy induced by mitochondrial energetic status. Cell Metab 2013; 17: 719-30.
77. Campos T, Ziehe J, Palma M, et al., Rheb promotes cancer cell survival through p27Kip1-dependent activation of autophagy. Mol Carcinog 2015; doi: 10.1002/mc.22272.
78. Jeon S-M, Chandel NS, Hay N., AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485: 661-5.
79. Ding W-X, Yin X-M., Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem 2012; 393: 547-64.
80. Jones RG, Thompson CB., Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23: 537-48.
81. Vander Heiden MG, Cantley LC, Thompson CB., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
82. Shackelford DB, Shaw RJ., The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-75.
83. Inoki K, Zhu T, Guan K-L., TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-90.
84. Gwinn DM, Shackelford DB, Egan DF, et al., AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-26.
85. Zheng M, Wang Y-H, Wu X-N, et al., Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. Nat Cell Biol 2011; 13: 263-72.
86. Park HU, Suy S, Danner M, et al., AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8: 733-41.
87. Shaw RJ, Kosmatka M, Bardeesy N, et al., The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004; 101: 3329-35.
88. Besson A, Gurian-West M, Schmidt A, et al., p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004; 18: 862-76.
89. Besson A, Hwang HC, Cicero S, et al., Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007; 21: 1731-46.
90. Wu FY, Wang SE, Sanders ME, et al., Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 2006; 66: 2162-72.
91. Borriello A, Cucciolla V, Oliva A, et al., p27Kip1 metabolism: a fascinating labyrinth. Cell Cycle 2007; 6: 1053-61.
92. Short JD, Houston KD, Dere R, et al., AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 2008; 68: 6496-506.
93. Liang J, Shao SH, Xu Z-X, et al., The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218-24.
94. Parkhitko A, Myachina F, Morrison TA, et al., Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci USA 2011; 108: 12455-60.
95. Roy A, Lahiry L, Banerjee D, et al., Increased cytoplasmic localization of p27kip1 and its modulation of RhoA activity during progression of chronic myeloid leukemia. PLoS One 2013; 8: e76527. doi: 10.1371/journal.pone.00 7.
96. Wander SA, Zhao D, Slingerland JM., p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res 2010; 17: 12-1 8.
97. Karbowniczek M, Zitserman D, Khabibullin D, et al., The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest 2010; 120: 93-102.
98. Sato T, Akasu H, Shimono W, et al., Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. J Biol Chem 2015; 290: 1096-105.
99. Roy M, Pear WS, Aster JC., The multifaceted role of Notch in cancer. Curr Opin Genet Dev 2007; 17: 52-9.
100. Takebe N, Miele L, Harris PJ, et al., Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 2015; 12: 445-64.
101. Wang Z, Li Y, Ahmad A, et al., Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010; 1806: 258-67.